Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,145.21 +66.35 (+0.82%) Bitcoin USD
63,534.34 -254.70 (-0.40%) CMC Crypto 200
1,320.29 -76.24 (-5.46%)
ABBV Jun 2024 75.000 call
| Previous close | 63.52 |
| Open | 63.52 |
| Bid | 77.75 |
| Ask | 81.75 |
| Strike | 75.00 |
| Expiry date | 2024-06-21 |
| Day's range | 63.52 - 63.52 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Yahoo Finance Video
PCE reading, Microsoft, Alphabet jump on earnings: Yahoo Finance
Investors are digesting the Fed's preferred inflation measure after the release of the Personal Consumption Expenditures (PCE) index.Big Tech is coming to the rescue on Wall Street. Microsoft (MSFT) and Alphabet (GOOGL, GOOG) are jumping following their latest earning reports. Both companies topped expectations and were helped by their AI businesses. The news comes after a rough day for stocks, with a weaker-than-expected GDP report and earnings from companies such as Meta (META), sending markets deep in the red. Today, we will hear from big names, including ExxonMobil (XOM), Chevron (CVX), Colgate-Palmolive (CL), and AbbVie (ABBV). Yahoo Finance trending tickers include Intel (INTC), Snap (SNAP), and Roku (ROKU). Key guests include:9 a.m. ET - Brian Rose -UBS Global Wealth Management Senior US Economist10:40 a.m. ET - Chris Peterson, Newell Brands CEO11:20 a.m. ET - Patrick Gelsinger, Intel CEO
Barrons.comAbbVie Raises Earnings Guidance Even as Humira Sales Continue to Drop
AbbVie raised its full-year earnings outlook despite continuing sales declines for autoimmune drug Humira. AbbVie said it expects adjusted earnings in 2024 of between $11.13 and $11.33 a share, up from previous guidance of $10.97 to $11.17 a share. Analysts surveyed by FactSet were expecting the biopharmaceutical company to post full-year earnings of $11.12 a share.
GuruFocus.comAbbVie Inc (ABBV) Q1 2024 Earnings: Adjusted EPS Tops Estimates Despite Revenue Challenges
Comprehensive Analysis of AbbVie's Latest Financial Performance
